STIMPOD NMS400 receives FDA 510(k) clearance 

January 12, 2010 - Xavant Technology (Pty) Ltd announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the STIMPOD NMS400 nerve stimulator (currently available as the STIMPOD NMS410) used for nerve location during Regional Anesthesia procedures. 

The clearance will enable Xavant Technology to expand the distribution of its re-usable range of STIMPOD nerve stimulators to include the US market. The STIMPOD range of nerve stimulators brings a higher level of nerve location precision into the US market with their unique nerve mapping and locating combination cables. A further feature also includes the unique charge transfer waveform, a feature that shows the anesthesiologist the exact charge that is being transferred to the patient, as well as the proximity indicator, alerting the anesthesiologist to possible nerve proximity.

Xavant Technology was the first company to introduce nerve mapping in the US market in 2003 with the NMS300 (marketed as the NeuroTrace III). The combined mapping/locating technique enabled  by the Mapping/Locating combination cable that is introduced with the latest STIMPOD nerve stimulator range completely innovates the practical use of nerve mapping as an everyday tool. With the auto-sense technology that is embedded in these cables, the anesthesiologist is now able to perform nerve mapping and nerve location without having to remove the mapping device from the site.